H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $72 from $70 and keeps a Buy rating on the shares following the Q4 report.

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), with a price target ...

President of NYU College Republicans resigns after calling Barron Trump ‘an oddity’ ...

Halozyme Therapeutics (HALO) reported $298.01 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 29.6%. EPS of $1.26 for the same period compares to ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.82 per share a year ago.

Elon Musk’s artificial-intelligence company xAI unveiled an improved version of its Grok chatbot and the model that powers it ...

Reports Q4 revenue $298.0M, consensus $285.7M. “I am excited to announce that the significant growth we achieved throughout the year culminated ...

Reports Q4 revenue $298.0M, consensus $285.7M. “I am excited to announce that the significant growth we achieved throughout the year culminated ...

Real-time index price for Nasdaq Composite [TR] (XCMP), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is expected to be announcing its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce ...